Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Small-Cap Snapshot: Papa John's climbs on media report the pizza maker could be a target of Restaurant Brands

CONMED, Quotient Technology and PTC Therapeutics are also seeing trading action

Papa John’s International Inc (NASDAQ:PZZA) is a top gainer in the wake of a DealReporter story that says the fast-food chain could be a possible target for Restaurant Brands International (NYSE:QSR). The pizza maker is said to be exploring a possible sale and has been locked in a legal battle with founder John Schnatter, who was pushed out as chairman after his alleged foul language and inappropriate behavior kicked off a firestorm in the media.

Papa John’s added 6.4% to $44.30.

CONMED (NASDAQ:CNMD) is also doing well after the medical technology company that provides surgical devices for minimally invasive procedures zipped past Wall Street’s estimates for revenue and profit in its fourth quarter. In the three months ending on December 31, the Utica, New York-based company posted adjusted earnings of $0.73 per share on revenue of $242.4 million.

CONMED shares climbed 8.6% to $72.50.

READ: Early Movers: IBM shares light up after fourth quarter beat, while Procter & Gamble Co is also on the up

Shares of Quotient Technology (NYSE:QUOT) are taking a hammering, meanwhile, after the digital promotions and analytics company unveiled preliminary fourth-quarter and full-year results which miss the company’s previous guidance and the Street’s consensus estimates. The company now expects to report sales of $106.5 million to $107.5 million for the fourth quarter and revenues of $386.5 million to $387.5 million for the year. Its earnings report will be broadcast after the market closes on February 12.

Quotient slipped 15.15% to $9.35.

PTC Therapeutics (NASDAQ:PTCT) is also having a rough day after announcing a secondary offering of 6.72 million shares at US$30.20 per share. PTC Therapeutics expects to close the offering on or about January 25. Underwriters also have an option for a period of 30 days to purchase an additional 1 million shares of stock at the public offering price.

PTC shares shed 11.1% to $29.34.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK